TY  - GEN
AU  - Ribrag,Vincent
AU  - Koscielny,Serge
AU  - Bosq,Jacques
AU  - Leguay,Thibaut
AU  - Casasnovas,Olivier
AU  - Fornecker,Luc-Mathieu
AU  - Recher,Christian
AU  - Ghesquieres,Hervé
AU  - Morschhauser,Franck
AU  - Girault,Stéphane
AU  - Le Gouill,Steven
AU  - Ojeda-Uribe,Mario
AU  - Mariette,Clara
AU  - Cornillon,Jerome
AU  - Cartron,Guillaume
AU  - Verge,Veronique
AU  - Chassagne-Clément,Catherine
AU  - Dombret,Hervé
AU  - Coiffier,Bertrand
AU  - Lamy,Thierry
AU  - Tilly,Hervé
AU  - Salles,Gilles
TI  - Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
SN  - 1474-547X
PY  - 2016///0801
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Bone Marrow Neoplasms
KW  - drug therapy
KW  - Burkitt Lymphoma
KW  - chemistry
KW  - Central Nervous System Neoplasms
KW  - Cyclophosphamide
KW  - Cytarabine
KW  - Doxorubicin
KW  - Drug Administration Schedule
KW  - Female
KW  - France
KW  - Humans
KW  - Hydrocortisone
KW  - Injections, Intravenous
KW  - Male
KW  - Methotrexate
KW  - Methylprednisolone
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Odds Ratio
KW  - Patient Selection
KW  - Prednisone
KW  - Proportional Hazards Models
KW  - Rituximab
KW  - Treatment Outcome
KW  - Vincristine
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(15)01317-3
ER  -